Research Pulse — 2026-09-06 | Brown Biotech

# Research Pulse — 2026-09-06
_Generated 2026-09-06 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 6일 (일요일) · Instantiating(구현 Day)**

9/6(구현) → 9/5(다양화) → 9/4(전이) → 9/3(집적) → 9/2(성숙) → 9/1(교정) → 8/31(수렴) → ... → 7/14(가속). Diversifying(9/5)된 기술들이 **구체적 구현(Instantiating) 단계로 이전하며 실세계 적용 사례와 산업 구체화를 동시에 입증하는 날** — Feldman et al.으로 AlphaFold3 adversarial sequence mutations에서 ** templated pattern matching vs biophysical reasoning 근본적 문제 확인**, confidence metric이 best structure를 35%에서만 선택 — protein structure AI의 근본적 한계 재확인(Current Opinion Structural Biology 2026), Lushington et al.으로 **first-in-human prime editing trial functional restoration 확인 + safety profile 긍정적** — prime editing 임상 이행里程碑(Caleb Lushington Molecular Therapy 2026), Ji et al.으로 **neuropsychiatric disorders에서 prime editing BBB penetration + neuron-targeted delivery开拓** — prime editing 신경계 적용 구체화(Neuroprotection 2026), Liu et al.으로 **scFoundation embeddings 25 cancer types pan-cancer survival prediction C-index 0.724 달성** — single-cell foundation model의 실세계 prognostic value 실증(Bioinformatics Advances 2026), Kunanayagam et al.으로 **FDA 44 CGTs through May 2025, 이中 14개 소아 사용** — CGT 소아 임상약리학 핵심 고려사항 체계화(Pediatric Research 2026), Mansinho et al.으로 **ADC solid tumor oncology standards 확립 + HER3/CLDN18.2/B7-H3 emerging targets** — ADC 고형종양 치료 표준화(Cancer 2026), Bai et al.으로 **BsADC modular blueprint 제시 + "toolbox" components 체계화** — bispecific ADC 설계 원칙 구체화(Archives Pharmacal Research 2026)가 동시에 진행된다.

Instantiating은 Diversifying의 다음 단계다. 오늘 6개 전선은 **다양화된 기술들이 구체적 구현 단계로 이전하며 실세계 적용 사례와 산업 구체화를 동시에 입증하는 날**이다.

*출처: [Feldman AlphaFold Adversarial Mutations Computational Structural Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Lushington Prime Editing First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Ji Prime Editing Neuropsychiatric Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/), [Liu scFoundation Survival Bioinformatics Advances 2026](https://consensus.app/papers/details/22f34170f63e5467badcc9ef75f0a619/), [Kunanayagam FDA CGT Pediatrics Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/), [Mansinho ADC Solid Tumor Cancer 2026](https://consensus.app/papers/details/f4ef0487a5d353d7a5dd4c01242062f2/), [Bai BsADC Modular Blueprint Archives Pharmacal Research 2026](https://consensus.app/papers/details/f30e4ec8a0bc51928c9f3e60dda31bd9/)*

*#InstantiatingDay #Feldman #AlphaFold #AdversarialMutations #ConfidenceMetric #Lushington #MolecularTherapy #PrimeEditing #FirstInHuman #FunctionalRestoration #Ji #Neuroprotection #Neuropsychiatric #BBB #NeuronTargeted #Liu #scFoundation #SurvivalPrediction #BioinformaticsAdvances #CIndex #Kunanayagam #PediatricResearch #FDA #CGT #44CGTs #14Pediatric #Mansinho #Cancer #ADC #SolidTumor #HER3 #CLDN182 #B7H3 #Bai #BsADC #ModularBlueprint #ArchivesPharmacalResearch #Instantiating #Diversifying #Industrialization #ClinicalTranslation #ProteinAI #CRISPR #PrimeEditing #Neuropsychiatric #FoundationModel #SurvivalPrediction #Pediatric #CellTherapy #GeneTherapy #ADC #BsAb #SolidTumor #Oncology #PrecisionMedicine*
---

### Post 2: CRISPR & Gene Editing — First-In-Human Prime Editing Trial와 Neuropsychiatric Disorders 적용 구체화

🪄 **[CRISPR/Gene Editing] First-in-human prime editing trial에서 functional restoration 확인 + safety profile 긍정적 확인(Lushington Molecular Therapy 2026) + Prime editing이 neuropsychiatric disorders에서 mutation-specific target selection + BBB penetration delivery开拓 확인(Ji Neuroprotection 2026) + Prime editing PE1→PE7 방법론 진화 + in vivo delivery 플랫폼별 전략 종합(Jong BMB Reports 2026): CRISPR의 Instantiating(구현) 동시 확인**

CRISPR 유전자 편집 기술의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[1][2][3].

**First-In-Human Prime Editing Trial: Functional Restoration + Safety Profile 확인[1]**
Caleb Lushington et al.(Molecular Therapy 2026)의 review는 first-in-human prime editing trial 결과를 분석한다. **PE의 장점**: double-strand breaks 없이 정확한 genomic substitutions, insertions, deletions 가능 — uncontrolled editing outcomes 회피. **Clinical translation 현황**: PE가 이제 clinic에 진입. **First-in-human study 결과**: functional restoration 확인. **Safety profile**: 현재까지 긍정적. **향후 방향**: efficiency 향상, delivery 개선, safety 보장. 핵심: First-in-human prime editing trial에서 functional restoration + 긍정적 safety profile — CRISPR Instantiating 완료.

**Prime Editing Neuropsychiatric Disorders: BBB Penetration + Neuron-Targeted Delivery开拓[2]**
Tianshan Ji et al.(Neuroprotection 2026)의 review는 prime editing의 신경계 적용을 분석한다. **정밀 편집**: double-strand breaks 없이 precise base substitutions, insertions, deletions 가능. **신경계 적용 장점**: nervous system에서 유전 돌연변이 교정 가능성. **BBB penetration 도전**: blood-brain barrier穿透 어려움. **Delivery platforms**: split-AAV systems, lipid nanoparticles, engineered peptides, compact Cas variants. **혈액-뇌 장벽 penetration 전략**: BBB-penetrant delivery platforms 개발. **Neuron-targeted delivery**: 신경세포 특이적 전달 체계. **Proof-of-concept**: in vitro · in vivo studies에서 monogenic neurodevelopmental disorders에서 correction + functional rescue 확인. **향후 방향**: improved editors, guide engineering, BBB-penetrant platforms, genome-wide safety evaluations. 핵심: Prime editing neuropsychiatric disorders 적용开拓 — BBB penetration + neuron-targeted delivery 구체화 Instantiating.

**Prime Editing: PE1→PE7 진화 + In Vivo Delivery 전략 체계화[3]**
U. Jong et al.(BMB Reports 2026)의 review는 prime editing 방법론 진화와 in vivo delivery 전략을 종합한다. **PE1→PE7 진화**: editing efficiency 향상, editable target range 확대, large genomic regions correction 가능. **Delivery platforms**: viral vectors, lipid nanoparticles, virus-like particles, electroporation. **In vivo 적용 분야**: genetic blindness, metabolic disorders, cardiovascular diseases, neuropsychiatric disorders. 핵심: Prime editing 방법론 진화 + platform별 delivery 전략 체계화 — CRISPR Instantiating 완성.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **An Nature Biotechnology**으로 **PE-eVLPs prime editing in vivo transient delivery**를, **Jong BMB Reports**으로 **PE1→PE7 methodology evolution + platform별 delivery**를 제시했다면, 오늘은 **Lushington Molecular Therapy**으로 **first-in-human prime editing trial functional restoration + safety profile**을(임상 이행里程碑 Instantiating), **Ji Neuroprotection**으로 **neuropsychiatric disorders BBB penetration + neuron-targeted delivery开拓**을(새 적용 영역 Instantiating), **Jong BMB Reports**으로 **PE1→PE7 methodology + in vivo delivery 전략 종합**을(구체적 구현 Instantiating) 동시에 제시한다. Diversifying(9/5) → CRISPR Instantiating(9/6).

실무 함의: 유전자 치료 전달팀에서 Lushington et al.의 first-in-human trial 결과를 분석하여 prime editing clinical pipeline 전략을 수립해야 한다.

*출처: [Lushington Prime Editing First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Ji Prime Editing Neuropsychiatric Disorders Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/), [Jong Prime Editing Updates BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/)*

*#CRISPR #GeneEditing #Lushington #MolecularTherapy #PrimeEditing #FirstInHuman #FunctionalRestoration #SafetyProfile #Ji #Neuroprotection #Neuropsychiatric #BBB #BloodBrainBarrier #NeuronTargeted #Delivery #Jong #BMBReports #PE7 #PrimeEditingEvolution #InVivoDelivery #SplitAAV #LipidNanoparticle #EngineeredPeptide #CompactCas #Monogenic #Neurodevelopmental #ProofOfConcept #InstantiatingDay #ClinicalTranslation #GeneCorrection #PrecisionMedicine #NervousSystem #GeneticDisorders #FunctionalRescue #GuideEngineering #GenomeWideSafety #ClinicalTrial #Safety #Efficiency*
---

### Post 3: AI 신약 — scFoundation Survival Prediction C-index 0.724와 Foundation Model Prognostic Value 실증

💊 **[AI 신약] scFoundation embeddings으로 25 cancer types TCGA에서 C-index 0.724 survival prediction 달성, 7개 cancer types에서 0.8 초과 확인(Liu Bioinformatics Advances 2026) + AI preclinical drug discovery translational hurdles 4가지(data quality · interpretability · heterogeneity · regulatory) 재확인(Cai Pharmaceuticals 2026) + Fully AI-discovered drug 0개 + AI-originated candidates Phase IIa efficacy / Phase I safety 이중성 재확인(Seyhan Critical Reviews Oncology Hematology 2026): AI drug discovery의 Instantiating(구현) 동시 확인**

AI-Driven Drug Discovery의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[4][5][6].

**scFoundation Survival Prediction: C-Index 0.724 + 7 Cancer Types 0.8 초과[4]**
Wei Liu et al.(Bioinformatics Advances 2026)의 연구는 scFoundation foundation model의 prognostic value를 분석한다. **대상**: 25 cancer types TCGA patient-level embeddings. **방법**: Embedding-Gene-Survival Prediction(EGSP) model. **성과**: mean C-index 0.724 across cancers. **7개 cancer types에서 0.8 초과**: pan-cancer setting에서 excellent performance. **초과 성능**: single-modality models · existing multi-omics survival approaches 모두 능가. **Biological programs**: tumor differentiation, immune activity, tumor-intrinsic growth 관련 interpretable biological programs 포착. **핵심**: scFoundation embeddings으로 survival prediction C-index 0.724 달성 — foundation model prognostic value Instantiating.

**AI Preclinical Drug Discovery: Translational Hurdles 4가지 재확인[5]**
Meng Cai et al.(Pharmaceuticals 2026)의 review: AI preclinical drug discovery의 4대 translational hurdle 재확인. **(i) data quality** — 불완전하거나 편향된 training data. **(ii) model interpretability** — black-box nature로 regulatory confidence 부족. **(iii) patient heterogeneity** — 임상시험 participants와 training data 간 불일치. **(iv) regulatory adaptation** — 기존 framework로 AI model 평가 어려움. **미래 방향**: multimodal AI, digital twins, closed-loop automation. 핵심: AI preclinical drug discovery 4대 hurdle 재확인 — AI drug discovery Instantiating.

**AI Drug Discovery: Phase IIa/Phase I 이중성 + AI-Originated Candidates 재확인[6]**
A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026): fully AI-discovered/designed drug 0개 승인 현실 + AI-originated candidates 임상 개발 진행 중. **Phase IIa efficacy**: AI-discovered candidate가 encouraging efficacy 달성. **Phase I safety signals**: 다른 candidate는 safety signals로 정체. **AlphaFold · MoleR · PocketCrafter · single-cell FMs · LLMs** 활용. 핵심: AI drug discovery 현주소 + Phase IIa/I 이중성 — Instantiating.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **Cai Pharmaceuticals**으로 **AI preclinical drug discovery 4대 translational hurdle**를, **Mao Frontiers Pharmacology**으로 **Phase IIa/I 이중성**을, **Seyhan Critical Reviews**으로 **fully AI-discovered drug 0개 + AI-originated 임상 진행**을 제시했다면, 오늘은 **Liu Bioinformatics Advances**으로 **scFoundation embeddings C-index 0.724 + 7 cancer types 0.8 초과**를(foundation model prognostic value 실증 Instantiating), **Cai Pharmaceuticals**으로 **4대 hurdle 재확인**을(계속적 한계 Instantiating), **Seyhan Critical Reviews**으로 **Phase IIa/I 이중성 재확인**을(현실 Instantiating) 동시에 제시한다. Diversifying(9/5) → AI drug discovery Instantiating(9/6).

실무 함의: AI drug discovery 협업팀에서 Liu et al.의 EGSP model 결과를 분석하여 foundation model-based prognostic biomarker development strategy를 수립해야 한다.

*출처: [Liu scFoundation Survival Prediction Bioinformatics Advances 2026](https://consensus.app/papers/details/22f34170f63e5467badcc9ef75f0a619/), [Cai AI Preclinical Drug Discovery Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fdbe56fb8a814115873a73d5/)*

*#AI #DrugDiscovery #Liu #BioinformaticsAdvances #scFoundation #SurvivalPrediction #CIndex #724 #7CancerTypes #08Exceed #FoundationModel #EGSP #EmbeddingGeneSurvival #TCGA #Pancancer #PrognosticValue #InterpretableAI #TumorDifferentiation #ImmuneActivity #Cai #Pharmaceuticals #TranslationalHurdles #DataQuality #Interpretability #Heterogeneity #Regulatory #Seyhan #CriticalReviews #OncologyHematology #PhaseIIa #PhaseI #SafetySignals #ZeroAIApproval #AIOriginated #ClinicalTrials #MultimodalAI #DigitalTwins #ClosedLoopAutomation #InstantiatingDay #FoundationModel #SurvivalAnalysis #Biomarker #PrecisionMedicine #Bioinformatics #Oncology #ComputationalBiology*
---

### Post 4: 단백질 AI — AlphaFold Adversarial Mutations Templated Pattern Matching vs Biophysical Reasoning 근본적 문제 확인

🔬 **[단백질 AI] Feldman et al.으로 AlphaFold3 adversarial sequence mutations에서 nonphysical structural invariance + confidence metric이 best structure를 35%에서만 선택 확인 — templated pattern matching vs biophysical reasoning 근본적 문제 재확인(Computational Structural Biotechnology 2026) + AlphaFold2 peptide structure prediction의 conformational dynamics 한계 + MD 보완 필요성 재확인(Zhang Biotechnology Advances 2026) + AlphaFold-like model의 protein-ligand drug discovery 적용 데이터 격차 재확인(Singh Current Opinion Structural Biology 2026): 단백질 AI의 Instantiating(구현) 동시 확인**

단백질 AI의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[7][8][9].

**AlphaFold3 Adversarial Mutations: Templated Pattern Matching vs Biophysical Reasoning 근본적 문제[7]**
Jonathan Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3 adversarial evaluation 결과를 제시한다. **200 proteins에서 point · deletion mutations 수행**: systematic adversarial evaluation. **핵심 발견 1 — Nonphysical Structural Invariance**: destabilizing substitutions · 10% deletions에도 predicted structures unchanged. **핵심 발견 2 — Confidence Metric 문제**: AlphaFold confidence metrics가 best available training-set template의 structural quality와 상관관계. **35% 이상 정확도 부재**: confidence metrics가 most accurate structure를 35% 미만에서만 선택. **ESMFold 비교**: ESMFold가 더 큰 mutation sensitivity 보여줌 — training objective 차이 시사. **Implications**: mutation-effect interpretation, confidence-guided model selection, sequence optimization workflows에 직접적 영향. **핵심**: AlphaFold templated pattern matching vs biophysical reasoning 근본적 문제 확인 — 단백질 AI Instantiating 한계 확인.

**AlphaFold2 Peptide Structure Prediction: Conformational Dynamics 한계 + MD 보완 필요성[8]**
Buke Zhang et al.(Biotechnology Advances 2026)의 review: AlphaFold2 peptide structure prediction의 conformational dynamics 한계 재확인. **한계 1 — conformational flexibility**: receptor binding 시에만 functional conformations 채택. **한계 2 — virtual screening 실패**: static prediction의 한계. **한계 3 — transient interactions · chemical modifications**: 다루지 못함. **보완 전략**: AlphaFold + molecular dynamics + free energy calculations + ensemble sampling 통합. 핵심: AlphaFold peptide prediction conformational dynamics 한계 + MD 보완 전략 — 단백질 AI Instantiating 한계.

**AlphaFold-Like Models: Protein-Ligand Drug Discovery 적용 데이터 격차[9]**
Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review: AlphaFold-like model의 drug discovery 적용 데이터 격차 재확인. **hierarchical framework**: 현재 models가 잘 수행하는 tasks vs challenging/unexplored tasks 구분. **필요한 것**: systematic dataset generation. 핵심: AlphaFold-like model의 SBDD 적용 데이터 격차 — 단백질 AI Instantiating 한계.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **Ren Chemical Science**으로 **AlphaFold-powered CDK20 inhibitor 30일 discovery**를, **Schauperl Journal Chemical Information**으로 **AlphaFold2 drug discovery impact + challenges**를, **Yang Signal Transduction**으로 **AlphaFold2 applications 종합**을 제시했다면, 오늘은 **Feldman Computational Structural Biotechnology**으로 **AlphaFold3 adversarial mutations에서 templated pattern matching vs biophysical reasoning 근본적 문제**를(새로운 근본적 한계 Instantiating), **Zhang Biotechnology Advances**으로 **peptide conformational dynamics 한계 + MD 보완 필요성**을(계속적 한계 Instantiating), **Singh Current Opinion**으로 **protein-ligand data gap 재확인**을(계속적 격차 Instantiating) 동시에 제시한다. Diversifying(9/5) → 단백질 AI Instantiating(9/6).

실무 함의: 전산단백질 설계팀에서 Feldman et al.의 adversarial evaluation 결과를 분석하여 AlphaFold confidence metric limitation을 고려한 protein design workflow를 수립해야 한다.

*출처: [Feldman AlphaFold Adversarial Mutations Computational Structural Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Zhang AlphaFold Peptide Structure Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/), [Singh AlphaFold-like Models Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)*

*#ProteinAI #AlphaFold #Feldman #ComputationalStructuralBiotechnology #AdversarialMutations #NonphysicalInvariance #ConfidenceMetric #35Percent #PatternMatching #BiophysicalReasoning #MutationEffect #Zhang #BiotechnologyAdvances #Peptide #ConformationalDynamics #MolecularDynamics #VirtualScreening #Singh #CurrentOpinion #StructuralBiology #ProteinLigand #DataGap #HierarchicalFramework #AlphaFold2 #AlphaFold3 #ESMFold #TrainingObjective #StructuralQuality #Invariance #Destabilizing #SequenceOptimization #InstantiatingDay #ProteinStructure #DrugDiscovery #ComputationalBiology #StructuralBiology #Limitations #ConfidenceMetric #PatternMatching #BiophysicalReasoning*
---

### Post 5: Single-Cell Multi-Omics Foundation Model — scFoundation Survival C-index 0.724와 Pan-Cancer Prognostic Value 실증

🬬 **[Single-Cell Multi-Omics Foundation Model] scFoundation embeddings으로 25 cancer types C-index 0.724 survival prediction 달성, 7개 cancer types에서 0.8 초과(Liu Bioinformatics Advances 2026) + CAPTAIN multimodal foundation model로 protein-driven intercellular dynamics + COVID-19 immune patterns 확인(Ji Nature Communications 2026) + PertAdapt condition-sensitive adaptation + 27 methods benchmark 재확인(Bai Bioinformatics 2026; Wei Nature Methods 2025): foundation model의 Instantiating(구현) 동시 확인**

Single-Cell Foundation Model의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[10][11][12].

**scFoundation Survival Prediction: C-Index 0.724 + Pan-Cancer Prognostic Value 실증[10]**
Wei Liu et al.(Bioinformatics Advances 2026)의 연구: scFoundation pretrained weights에서 patient-level embeddings 도출. **25 cancer types TCGA**: bulk RNA-seq data에서 survival prediction. **EGSP model**: foundation model embeddings + gene expression + clinical variables 통합. **성과**: mean C-index 0.724 across cancers. **7개 cancer types에서 C-index 0.8 초과**: excellent performance. **초과 성능**: single-modality models · existing multi-omics survival approaches 모두 능가. **Biological programs**: tumor differentiation, immune activity, tumor-intrinsic growth related prognostic embeddings 포착. **Non-redundant signals**: gene expression과 lower redundancy + complementary prognostic signals. **핵심**: scFoundation embeddings로 C-index 0.724 survival prediction 달성 — foundation model prognostic value Instantiating.

**CAPTAIN Multimodal: Protein-Driven Intercellular Dynamics + COVID-19 Immune Patterns[11]**
Boya Ji et al.(Nature Communications 2026): CAPTAIN multimodal foundation model로 COVID-19 severity 관련 immune interaction patterns 발견. **4M+ cells + 382 proteins**: concurrently measured transcriptomes + curated proteins. **Novel hypothesis generation**: protein-driven intercellular dynamics 관련 잠재적 immune interaction patterns. **COVID-19 severity link**: immune interaction patterns와 severity 연관 확인. **Generalization**: fine-tuning + zero-shot settings 모두에서 robust performance. 핵심: CAPTAIN multimodal로 COVID-19 immune interaction patterns 발견 — foundation model hypothesis generation Instantiating.

**PertAdapt: Condition-Sensitive Adaptation + 27 Methods Benchmark[12]**
Ding Bai et al.(Bioinformatics 2026): PertAdapt framework로 condition-sensitive adaptation 구현. **7개 perturbation datasets**: single-gene · double-gene 모두. **성과**: non-pretrained · FM baselines 모두 consistent outperform. **27 methods benchmark 재확인(Wei Nature Methods 2025)**: foundation models의 generalizability 한계 체계적 평가. 핵심: PertAdapt condition-sensitive adaptation + benchmark 한계 재확인 — foundation model Instantiating 한계.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **Bai PertAdapt**으로 **condition-sensitive adaptation**을, **Wei Nature Methods**으로 **27 methods · 29 datasets benchmark**를, **Gavriilides Computational Structural Biotechnology**으로 **perturbation modeling methods review**를 제시했다면, 오늘은 **Liu Bioinformatics Advances**으로 **scFoundation C-index 0.724 + 7 cancer types 0.8 초과**를(prognostic value 실증 Instantiating), **Ji Nature Communications**으로 **CAPTAIN COVID-19 immune interaction patterns + novel hypothesis generation**을(계속적 hypothesis generation Instantiating), **Bai Bioinformatics**으로 **PertAdapt condition-sensitive adaptation 재확인**을(계속적 adaptation Instantiating) 동시에 제시한다. Diversifying(9/5) → Foundation model Instantiating(9/6).

실무 함의: 단일세포 연구팀에서 Liu et al.의 EGSP model 결과를 분석하여 foundation model-based cancer prognosis biomarker development strategy를 수립해야 한다.

*출처: [Liu scFoundation Survival Prediction Bioinformatics Advances 2026](https://consensus.app/papers/details/22f34170f63e5467badcc9ef75f0a619/), [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Bai PertAdapt Bioinformatics 2026](https://consensus.app/papers/details/1b9008e455eb5a8099daee1c1036700a/), [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/)*

*#SingleCell #FoundationModel #Liu #BioinformaticsAdvances #scFoundation #SurvivalPrediction #CIndex #724 #7CancerTypes #08Exceed #EGSP #PanCancer #TumorDifferentiation #ImmuneActivity #PrognosticValue #Ji #CAPTAIN #NatureCommunications #Multimodal #COVID19 #ImmuneInteraction #ProteinDriven #ZeroShot #FineTuning #Bai #PertAdapt #ConditionSensitive #Adaptation #Bioinformatics #Wei #NatureMethods #Benchmark #27Methods #Generalizability #InstantiatingDay #SurvivalAnalysis #Biomarker #PrecisionOncology #BulkRNA #TCGA #Embedding #ComplementaryPrognosticSignals #CellularState #COVID19 #FoundationModel #MultiOmics #Perturbation*
---

### Post 6: FDA/규제 — FDA 44 CGTs 14개 소아 + CGT 소아 임상약리학 핵심 고려사항

📋 **[FDA/규제] FDA 44 CGTs through May 2025, 이中 14개 소아 사용 확인(Kunanayagam Pediatric Research 2026) + CGT 소아 임상약리학 핵심 고려사항 체계화(Kunanayagam Pediatric Research 2026) + FDA platform-aligned risk-based framework + AI/ML dose selection · safety evaluation · durability prediction 지원 구체화(Oo Journal Clinical Pharmacology 2026): FDA/규제의 Instantiating(구현) 동시 확인**

FDA/규제의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[13][14][15].

**FDA 44 CGTs Through May 2025: 14개 소아 사용 현황[13]**
S. Kunanayagam et al.(Pediatric Research 2026)의 review는 FDA CGT approvals의 소아 적용 현황을 분석한다. **44개 CGTs**: through May 2025. **14개 소아 사용**: pediatric use approved( cord blood 제외). **치료 분야**: diseases and conditions that cannot be effectively managed with small-molecule drugs and therapeutic proteins. **핵심 고려사항**: pharmacokinetic · first-in-human dosing considerations unique to cell and gene therapies. **In vivo gene therapies**: vector shedding, biodistribution. **Ex vivo gene therapies**: modification outside body before re-infusion. **Traditional PK principles 불적용**: ex vivo gene therapies. **Cellular kinetics**: expansion · persistence relevant for CAR-T · TIL therapies. **Preclinical models 의존**: safety, efficacy, dose selection inform. **Rare disease · pediatric challenges**: small patient populations · importance of preclinical evidence. 핵심: FDA 44 CGTs · 14개 소아 사용 현황 + 소아 임상약리학 핵심 고려사항 체계화 — FDA 규제 Instantiating.

**CGT 소아 임상약리학: 핵심 고려사항 체계화[14]**
Kunanayagam et al.(Pediatric Research 2026): 소아 CGT 임상약리학 핵심 고려사항 체계화. **IMPACT**: pediatric rare disease clinical pharmacology considerations for CGTs. **Advanced therapeutics vs traditional PK/PD frameworks**: 비교 분석. **Preclinical modeling**: safety, efficacy, first-in-human dosing guided by related therapies. **Clinical trial design**: 소아 특이적 고려사항. **Regulatory guidance**: 소아용 advanced therapeutic products를 위한 practical primer. **미래 방향**: 소아에서의 CGT development 확대. 핵심: CGT 소아 임상약리학 핵심 고려사항 체계화 — FDA 규제 Instantiating 완성.

**FDA Platform-Aligned Risk-Based Framework + AI/ML Integration[15]**
C. Oo et al.(Journal of Clinical Pharmacology 2026): FDA gene therapy approvals의 진화와 future directions. **Platform-aligned initiatives**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **AI/ML analytics**: dose selection, safety evaluation, durability prediction 지원. **Persistent issues**: high upfront costs, manufacturing complexity, payer constraints. **미래 방향**: durable benefit, equitable access, long-term safety. 핵심: FDA platform-aligned risk-based framework + AI/ML integration 구체화 — FDA 규제 Instantiating.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **Bach Cancer Cell International**으로 **CAR-T·TIL convergence + 3-stage barrier framework**를, **Shahzad Clinical Pharmacology Therapeutics**으로 **CGT postmarketing requirement 문제**를, **Oo Journal Clinical Pharmacology**으로 **platform-aligned risk-based framework**를 제시했다면, 오늘은 **Kunanayagam Pediatric Research**으로 **FDA 44 CGTs · 14개 소아 사용 현황**을(소아 적용 Instantiating), **Kunanayagam Pediatric Research**으로 **CGT 소아 임상약리학 핵심 고려사항 체계화**를(새 영역 Instantiating), **Oo Journal Clinical Pharmacology**으로 **AI/ML dose selection · safety evaluation · durability prediction 지원**을(AI 규제 통합 Instantiating) 동시에 제시한다. Diversifying(9/5) → FDA 규제 Instantiating(9/6).

실무 함의: 규제 기획팀에서 Kunanayagam et al.의 소아 CGT 임상약리학 고려사항을 분석하여 pediatric CGT regulatory strategy를 수립해야 한다.

*출처: [Kunanayagam FDA CGT Pediatrics Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/), [Oo FDA Gene Therapy Approvals Journal Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)*

*#FDA #Regulatory #Kunanayagam #PediatricResearch #CGT #44CGTs #14Pediatric #PediatricUse #Pharmacokinetics #FirstInHuman #Dosing #VectorShedding #Biodistribution #ExVivo #InVivo #CAR-T #TIL #Expansion #Persistence #PreclinicalModels #RareDisease #Oo #JournalClinicalPharmacology #PlatformAligned #RiskBased #PlausibleMechanism #CMC #AdvancedManufacturing #AI #ML #DoseSelection #SafetyEvaluation #DurabilityPrediction #InstantiatingDay #CellTherapy #GeneTherapy #Pediatric #ClinicalPharmacology #RegulatoryScience #Manufacturing #EquitableAccess #LongTermSafety*
---

### Post 7: Spatial Transcriptomics & ADC — ADC Solid Tumor Standards 확립과 BsADC Modular Blueprint 구체화

🗺️ **[Spatial Transcriptomics / ADC Convergence] Mansinho et al.으로 ADC solid tumor oncology standards 확립, HER3/CLDN18.2/B7-H3 emerging targets + biomarker-driven patient selection + earlier lines of therapy integration(Cancer 2026) + Bai et al.으로 BsADC modular blueprint + "toolbox" components 체계화, bispecific ADC 설계 원칙 구체화(Archives Pharmacal Research 2026) + Pan-cancer 12 cancer types 56 LCPs · 13 niches + Niche_4/Niche_11 prognostic biomarkers 재확인(Li Cell Reports Medicine 2026): spatial transcriptomics와 ADC convergence의 Instantiating(구현) 동시 확인**

Spatial Transcriptomics와 ADC convergence의**구체적 구현(Instantiating)**이 출처에서 동시에 확인된다[16][17][18].

**ADC Solid Tumor Oncology: Standards 확립 + HER3/CLDN18.2/B7-H3 Emerging Targets[16]**
A. Mansinho et al.(Cancer 2026)의 review는 ADC의 solid tumor oncology 통합을 분석한다. **ADC standards**: precision oncology에서 ADC의 standards of care 확립. **적용 분야**: breast, gynecologic, gastrointestinal, lung cancers. **Emerging targets**: HER3, CLDN18.2, B7-H3. **Mechanisms of resistance**: antigen loss, impaired internalization, payload-specific adaptations. **Bispecific · dual-payload designs**: resistance 극복 전략. **Immunotherapy · targeted agents combinations**: rational combinations. **Biomarker-driven patient selection**: predictive biomarkers로 patient selection. **Earlier lines of therapy integration**: frontline treatment로의 확대. **향후 방향**: deeper · more durable responses across broad spectrum of solid tumors. 핵심: ADC solid tumor standards 확립 + emerging targets + biomarker-driven patient selection — ADC Instantiating.

**BsADC Modular Blueprint: "Toolbox" Components 체계화[17]**
Yulin Bai et al.(Archives Pharmacal Research 2026)의 review는 BsADC의 modular blueprint를 제시한다. **Bispecific ADC**: bispecific antibodies + ADCs의 combination. **Enhanced recognition**: dual targeting으로 enhanced recognition capabilities. **Faster internalization**: bispecific design으로 faster drug internalization. **Therapeutic index improvement**: potential improvement of therapeutic index. **Modular "toolbox" components**: BsADC 설계의 기본 구성요소 체계화. **Bispecific antibodies characteristics**: BsADC construction에 필요한 요구사항. **Advantages over traditional ADCs**: conventional ADCs 대비 BsADC의 장점 분석. **핵심**: BsADC modular blueprint + "toolbox" components 체계화 — bispecific ADC Instantiating.

**Pan-Cancer Spatial TME: 12 Cancer Types · 56 LCPs · 13 Niches + Niche_4/Niche_11[18]**
Jiarong Li et al.(Cell Reports Medicine 2026): pan-cancer spatial transcriptomic analysis 재확인. **56개 LCPs**: tumor spatial microenvironment 내에서. **13개 recurrent niches**: niche-shared · niche-specific interactions. **Niche_4(macrophages + tumor cells)**: poor prognosis, immunotherapy resistance. **Niche_11(macrophages + immune cells)**: better survival, treatment response. 핵심: Pan-cancer 12 types · 56 LCPs · 13 niches + Niche_4/Niche_11 prognostic biomarkers — spatial TME Instantiating.

**9월 5일 Diversifying vs 오늘의 차별점**: 9/5가 **Nguyen Clinical & Translational Immunology**으로 **spatial omics TME profiling clinical translation 도전 3가지**를, **Mo Nature**으로 **3D tumor structure reconstruction**을 제시했다면, 오늘은 **Mansinho Cancer**으로 **ADC solid tumor standards 확립 + HER3/CLDN18.2/B7-H3 emerging targets + biomarker-driven patient selection**을(ADC Instantiating), **Bai Archives Pharmacal Research**으로 **BsADC modular blueprint + toolbox components 체계화**를(bispecific ADC Instantiating), **Li Cell Reports Medicine**으로 **56 LCPs · 13 niches + Niche_4/Niche_11 prognostic biomarkers 재확인**을(spatial TME Instantiating) 동시에 제시한다. Diversifying(9/5) → Spatial/ADC Instantiating(9/6).

실무 함의: ADC/BsADC 개발팀에서 Mansinho et al.의 emerging targets 분석을 참조하여 bispecific ADC target selection strategy를 수립해야 한다.

*출처: [Mansinho ADC Solid Tumor Oncology Cancer 2026](https://consensus.app/papers/details/f4ef0487a5d353d7a5dd4c01242062f2/), [Bai BsADC Modular Blueprint Archives Pharmacal Research 2026](https://consensus.app/papers/details/f30e4ec8a0bc51928c9f3e60dda31bd9/), [Li Pan-Cancer Spatial TME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #ADC #Mansinho #Cancer #ADCSolidTumor #StandardsOfCare #HER3 #CLDN182 #B7H3 #EmergingTargets #Biomarker #PatientSelection #EarlierLines #Resistance #AntigenLoss #Internalization #Bispecific #DualPayload #Bai #ArchivesPharmacalResearch #BsADC #ModularBlueprint #Toolbox #BispecificAntibody #Internalization #TherapeuticIndex #ModularDesign #Li #CellReportsMedicine #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Macrophages #Prognosis #Survival #ImmunotherapyResistance #InstantiatingDay #SolidTumor #Oncology #PrecisionMedicine #Biomarker #PatientSelection #BispecificADC #ADC #DrugDevelopment #Engineering #SpatialBiology #TME #Microenvironment #CancerAtlas #ResistanceMechanisms #TargetedTherapy*
---

### Post 8: 오늘의 요약 — Instantiating(구현 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

9/6(Instantiating)의 핵심: Diversifying(9/5)된 기술들이 **구체적 구현(Instantiating) 단계로 이전하며 실세계 적용 사례와 산업 구체화를 동시에 입증하는 날**이었다.

**1. First-In-Human Prime Editing Trial Functional Restoration + Safety Profile(Lushington Molecular Therapy 2026) + Neuropsychiatric Disorders BBB Penetration + Neuron-Targeted Delivery开拓(Ji Neuroprotection 2026)**: PE clinical translation milestone 달성 + 신경계 적용 구체화 — CRISPR Instantiating. [Lushington Molecular Therapy 2026; Ji Neuroprotection 2026]

**2. scFoundation Embeddings C-index 0.724 + 7 Cancer Types 0.8 초과(Liu Bioinformatics Advances 2026)**: EGSP model로 foundation model prognostic value 실증 — AI drug discovery / foundation model Instantiating. [Liu Bioinformatics Advances 2026]

**3. AlphaFold3 Adversarial Mutations Templated Pattern Matching vs Biophysical Reasoning 근본적 문제(Feldman Computational Structural Biotechnology 2026)**: confidence metric이 best structure를 35% 미만에서만 선택 — protein AI Instantiating 한계. [Feldman Computational Structural Biotechnology 2026]

**4. FDA 44 CGTs · 14개 소아 사용(Kunanayagam Pediatric Research 2026) + CGT 소아 임상약리학 핵심 고려사항 체계화**: pharmacokinetic/first-in-human dosing considerations unique to cell and gene therapies — FDA 규제 Instantiating. [Kunanayagam Pediatric Research 2026]

**5. ADC Solid Tumor Standards 확립 + HER3/CLDN18.2/B7-H3 Emerging Targets(Mansinho Cancer 2026) + BsADC Modular Blueprint + Toolbox Components 체계화(Bai Archives Pharmacal Research 2026)**: biomarker-driven patient selection + earlier lines of therapy integration + modular bispecific ADC 설계 원칙 구체화 — ADC/bsAb Instantiating. [Mansinho Cancer 2026; Bai Archives Pharmacal Research 2026]

**6. Pan-Cancer 12 Cancer Types · 56 LCPs · 13 Niches + Niche_4/Niche_11 재확인(Li Cell Reports Medicine 2026) + scFoundation Prognostic Value(Liu Bioinformatics Advances 2026)**: Niche_4(poor prognosis) · Niche_11(better survival) + C-index 0.724 — spatial TME / foundation model Instantiating. [Li Cell Reports Medicine 2026; Liu Bioinformatics Advances 2026]

**9월 7일 전망**: Instantiating된 기술들의 실세계 적용 속도와 산업 구체화가 핵심 변수. 특히 first-in-human prime editing trial의 추가 데이터, Feldman et al.의 adversarial evaluation 후속 연구, ADC emerging targets의 임상 데이터, FDA 소아 CGT guidelines 정착이 관전.

*출처: [Lushington Prime Editing First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Ji Prime Editing Neuropsychiatric Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/), [Jong Prime Editing Updates BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Liu scFoundation Survival Bioinformatics Advances 2026](https://consensus.app/papers/details/22f34170f63e5467badcc9ef75f0a619/), [Feldman AlphaFold Adversarial Computational Structural Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Zhang AlphaFold Peptide Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/), [Singh AlphaFold-like Models Current Opinion 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Bai PertAdapt Bioinformatics 2026](https://consensus.app/papers/details/1b9008e455eb5a8099daee1c1036700a/), [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/), [Kunanayagam FDA CGT Pediatrics Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/), [Oo FDA Gene Therapy Journal Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Mansinho ADC Solid Tumor Cancer 2026](https://consensus.app/papers/details/f4ef0487a5d353d7a5dd4c01242062f2/), [Bai BsADC Modular Blueprint Archives Pharmacal Research 2026](https://consensus.app/papers/details/f30e4ec8a0bc51928c9f3e60dda31bd9/), [Li Pan-Cancer TME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Cai AI Preclinical Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Seyhan AI Drug Discovery Critical Reviews 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)*

*#InstantiatingDay #Summary #Lushington #PrimeEditing #FirstInHuman #FunctionalRestoration #Ji #Neuropsychiatric #BBB #NeuronTargeted #Jong #PE7 #Liu #scFoundation #SurvivalPrediction #CIndex #724 #BioinformaticsAdvances #Feldman #AlphaFold #AdversarialMutations #ConfidenceMetric #35Percent #PatternMatching #Zhang #Peptide #ConformationalDynamics #Singh #AlphaFoldLike #DataGap #Ji #CAPTAIN #COVID19 #Bai #PertAdapt #Kunanayagam #Pediatric #14Pediatric #CGT #44CGTs #Oo #PlatformAligned #RiskBased #Mansinho #ADC #HER3 #CLDN182 #B7H3 #Biomarker #PatientSelection #Bai #BsADC #ModularBlueprint #Toolbox #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Cai #TranslationalHurdles #Seyhan #ZeroAIApproval #Instantiating #Diversifying #ClinicalTranslation #Industrialization #GeneEditing #PrimeEditing #FoundationModel #ProteinAI #FDA #Regulatory #Pediatric #CellTherapy #ADC #BsAb #SolidTumor #PrecisionMedicine #SpatialBiology #TME #Survival #Biomarker #Prognosis*
---

## Sources

[1] [Lushington et al. — A primer on prime: A prime editing update from advances to first-in-human trial. Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/)

[2] [Ji et al. — Prime editing in neuropsychiatric disorders: From mutation-specific target selection to clinical translation. Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/)

[3] [Jong et al. — Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications. BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/)

[4] [Liu et al. — Leveraging single-cell foundation models for accurate survival outcome prediction. Bioinformatics Advances 2026](https://consensus.app/papers/details/22f34170f63e5467badcc9ef75f0a619/)

[5] [Cai et al. — From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation. Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)

[6] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)

[7] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)

[8] [Zhang et al. — AlphaFold-based peptide structure prediction: Opportunities, limitations, and future directions. Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/)

[9] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)

[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)

[11] [Bai et al. — PertAdapt: unlocking single-cell foundation models for genetic perturbation prediction via condition-sensitive adaptation. Bioinformatics 2026](https://consensus.app/papers/details/1b9008e455eb5a8099daee1c1036700a/)

[12] [Wei et al. — Benchmarking algorithms for generalizable single-cell perturbation response prediction. Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/)

[13] [Kunanayagam et al. — Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics. Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)

[14] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. The Journal of Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)

[15] [Mansinho et al. — Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions. Cancer 2026](https://consensus.app/papers/details/f4ef0487a5d353d7a5dd4c01242062f2/)

[16] [Bai et al. — Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics. Archives Pharmacal Research 2026](https://consensus.app/papers/details/f30e4ec8a0bc51928c9f3e60dda31bd9/)

[17] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)